Skip to main content

Table 1 Main characteristics of the included studies in the meta‐analysis of weight loss and outcomes after AF ablation

From: Association between weight loss and outcomes in patients undergoing atrial fibrillation ablation: a systematic review and dose–response meta-analysis

Refences (First author, Year, Country/Region)

Source of individuals

Outcomes

Study design

AF diagnosis

Methods of weight loss

N

Age# (year) Male# (%) BMI#

Weight loss (%)

RR (95% CI)

Follow-up times (months)

Adjusted covariates

Clinical trial

Gessler 2021, Germany

SORT-AF trial

AF recurrence

AF burden

Randomized, open-labeled clinical trial

ECG, ILR interrogation

Lifestyle

67/66

58.7/62.1,64/62, 34.9/34.8

4.5

1.14 (0.37–3.61)

12

NA

Observational studies

Pathak 2014, Australian

ARREST-AF Cohort Study

AF recurrence  duration and symptoms of AF

Prospective Cohort

ECG

Lifestyle

149

57.7, 63.8, 32.7

13.1

0.21 (0.09–0.49)

24

Multiple procedures,

type of AF,

poor BP

control

Bunch 2016,

USA

LDS Hospital, Intermountain Medical Center

AF recurrence

Prospective Cohort

ECG

NA

288

36.3, 59.3, 36

4.5

0.73 (0.50–1.10)

36

Multivariable

adjusted&

Mohanty 2017, USA

St. David’s Medical Center

AF recurrence  symptom severity of AF  quality of life

Prospective Cohort

ECG

Lifestyle

90

62.7, 72.2, 37.6

20.5

0.89 (0.52–1.53)

12

NA

Donnellan 2019,

USA

Cleveland Clinic

AF recurrence

Retrospective Cohort

ECG, Holter

Bariatric surgery

239

64.6, 55.6, 41.1

20.6

0.14 (0.05–0.39)

60

HbA1C, presenting rhythm at the time of ablation, EFV, BMI, LA

Ding 2020, UK

Liverpool

Heart and Chest Hospital

AF recurrence

Prospective Cohort

ECG, Holter

Lifestyle

92

64.5, 56.5, 36.0

6

1.85 (0.70–4.90)

12

Sex, type of AF, age

Y Lau 2020,

UK

Glasgow Royal Infirmary

AF recurrence

Prospective Cohort

NA

Lifestyle

146

NA, NA,

30.4

4.2

0.33 (0.29–0.85)

6

NA

Shah 2020,

USA

The University of Rochester Medical Center

AF recurrence

Prospective Cohort

NA

NA

146

61, 67,31

22

0.29 (0.11–0.80)

12

Multivariable adjusted&

  1. AF Atrial fibrillation, ARREST-AF Aggressive Risk factor reduction study for atrial fibrillation, CARDIO-FIT Study cardio- respiratory fitness, SORT-AF Supervised obesity reduction trial for AF, ILR Implantation loop recorder, UK United Kingdom, USA United States of America, ECG Electrocardiograph, BMI Body mass index, HbA1C Hemoglobin A1C, BS Bariatric surgery, EFV Epicardial fat volume, LA Left atrium & unclear the exactly adjusted covariate, NA not available
  2. *AF burden was quantified by using the validated Atrial Fibrillation Severity Scale
  3. #The first number refers to the loss weight group and the second to the control; one column refers to the mean or median values of the overall cohort